Efficacy Of Levonorgestrel-releasing Intrauterine System Research Articles

The second generation endometrial ablation (NovaSure) improves efficacy of levonorgestrel-releasing intrauterine system in management of adenomyosis

To determine the efficacy of second generation endometrial ablation (NovaSure) combined with levonorgestrel-releasing intrauterine system (Mirena) in the treatment of adenomyosis. Clinical data of patients with adenomyosis admitted in Women's Hospital, Zhejiang University School of Medicine from January 2015 to December 2018 were retrospectively analyzed. Among 66 patients, 44 received Mirena placement only (control group) and 22 received Mirena placement and NovaSure treatment (study group). The menstruation blood loss, dysmenorrhea score, uterine size, expulsion rate of Mirena and the patients' satisfaction rate were assessed in two groups. There was a significant reduction in menstruation blood loss (P<0.05) and significant improvement in dysmenorrhea (P<0.05) after the treatment in both groups. The patients in study group had more marked improvement in menstruation blood loss than those in control group (P<0.05). The patients' satisfaction was higher and the expulsion rate of Mirena was lower in study group than that in control group (all P<0.05). The score of dysmenorrhea and the size of uterine had no significant difference between two groups (all P>0.05). NovaSure can improve the efficacy of Mirena in treatment of adenomyosis.

Efficacy and fertility outcomes of levonorgestrel-releasing intra-uterine system treatment for patients with atypical complex hyperplasia or endometrial cancer: a retrospective study.

ObjectiveTo investigate the efficacy of levonorgestrel-releasing intra-uterine system (LNG-IUS) treatment in patients affected by atypical complex hyperplasia/endometrial cancer (ACH/EC) wishing to preserve their fertility and to present fertility outcomes of those patients who actively tried to conceive.MethodsData of consecutive women with ACH/EC who underwent fertility-sparing treatment using LNG-IUS were retrospectively evaluated.ResultsOverall, 48 patients and the mean (±standard deviation) length of follow-up was 82.6±47.2 months. Among patients with ACH, 25/28 (89.3%) had a complete response (CR), 2/28 (7.1%) had a partial response (PR) and 1/28 (3.6%) had a progressive disease (PD). Mean (±standard deviation) time to CR was 6.7±4.0 months. Among patients with G1 EC, 13/16 (81.3%) had a CR, 1/16 (6.3%) had a PR and 2/16 (12.5%) had a PD. Mean (±standard deviation) time to CR was 5.0±2.9 months. Among patients with G2 EC, 3/4 (75.0%) had a CR and 1/4 (25.0%) had a PD. Mean (±standard deviation) time to CR was 4.0±0 months. Only 19 (39.6%) patients who had CR actually attempted to conceive. Eleven (57.9%) women tried to conceive naturally while 8 (42.1%) women underwent an in vitro fertilization (IVF). Fourteen (73.7%) patients wishing to conceive achieved a pregnancy (6 spontaneously and 8 through IVF).ConclusionsFertility-sparing treatment of patient with ACH/EC with LNG-IUS achieves high regression rates and good fertility outcomes. Future larger multi-institutional studies should be designed to confirm these preliminary findings.

Clinical efficacy of levonorgestrel releasing intrauterine system for the treatment of adenomyosis in perimenopausal women

Background: The aim of this study was to evaluate the efficacy of levonorgestrel-releasing intrauterine system (LNG-IUS) in the treatment of menorrhagia, dysmenorrhea, and poor quality of life caused by adenomyosis in perimenopausal women. Materials and Methods: Ninety-six women with menorrhagia, dysmenorrhea, and poor quality of life with adenomyosis in perimenopausal women were included and were invited to complete a SF-36 Health Survey. Excluded were cervical and endometrial lesions that underwent a Pap smear, transvaginal sonography, and endometrial biopsy. LNG-IUS was inserted in the postmenstrual phase. Blood loss was assessed by pictorial blood loss assessment chart (PBAC), and dysmenorrhea intensity was assessed by a visual analogue scale (VAS). The patients were followed up after one, three, six, 12, and after 18 months. The participations are asked to complete the short form 36 (SF- 36) health survey questionnaires. Results: The menstrual blood size was (60.287 &#x00B1; 21.832) (41.186 &#x00B1; 16.153), (30.988 &#x00B1; 15.670), (19.238 &#x00B1; 13.649), (16 &#x00B1; 11.464) after treatment one, three, six, 12, and after 18 months, respectively, which reduced significantly compare with before treatment (88.691 &#x00B1; 33.775, p p Conclusion: These data suggest that LNG-IUS is a safe and effective option for reduces menorrhagia, relieve dysmenorrhea, and improve the quality of life in patients with adenomyosis from perimenopausal women.

Clinical Efficacy of Levonorgestrel Releasing Intrauterine System for the Treatment of Adenomyosis in Perimenopausal Women

Background: The aim of this study was to evaluate the efficacy of levonorgestrel-releasing intrauterine system (LNG-IUS, Mirena) in the treatment of menorrhagia, dysmenorrhea and poor quality of life caused by adenomyosis in perimenopausal women. Patients and methods: Ninety-six women with menorrhagia, dysmenorrhea and poor quality of life with adenomyosis in perimenopausal women were included and were invited to complete a SF-36 Health Survey. Exclude cervical and endometrial lesions through underwent a Pap smear, transvaginal sonography and endometrial biopsy. LNG-IUS was inserted in the postmenstrual phase. Blood loss was assessed by pictorial blood loss assessment chart (PBAC), and dysmenorrhea intensity was assessed by a visual analogue scale (VAS). They were followed up after 1 month, 3 months, 6 months, 12 months, and after 18 months. The participations are asked to complete the short form 36 (SF-36) health survey questionnaires. Results: The menstrual blood size was (60.287 ± 21.832) (41.186 ± 16.153), (30.988 ± 15.670), (19.238 ± 13.649), (16 ± 11.464) after treatment 1, 3, 6, 12, and after 18 months, respectively, which reduced significantly compare with before treatment (88.691 ± 33.775, P< 0.05). The VAS of dysmenorrheal dropped continuously and significantly from the baseline score of (74.968 ± 15.889) to (38.797 ± 16.781), (24.857 ± 16.595), (15.840 ± 14.305), (10.784 ± 13.593) and (8.196 ± 12.919), respectively, after treatment 1, 3, 6, 12, and after 18 months of the LNG-IUS insertion (P < 0.05). The results of SF-36 Health Survey shown the quality of life was significantly improved. Conclusion: These data suggest that LNG-IUS is a safe and effective option for reduces menorrhagia, relieve dysmenorrhea and improve the quality of life in patients with adenomyosis from perimenopausal women.

Efficacy of levonorgestrel releasing intrauterine system for the treatment of menorrhagia due to benign uterine lesions in perimenopausal women

Aims:To evaluate the efficacy of levonorgestrel-releasing intrauterine system (LNG-IUS, Mirena, Bayer Healthcare) in the treatment of menorrhagia caused by benign lesions of the uterus in perimenopausal women.Settings and Design:A prospective observational study was conducted to study the efficacy of levonorgestrel intrauterine device in the treatment of menorrhagia due to benign lesions of the uterus in perimenopausal women.Materials and Methods:Forty women with menorrhagia, due to benign conditions like idiopathic menorrhagia, fibroid (not more than 12 weeks size) or adenomyosis, attending our out-patient department were included in the study. All the women underwent a PAP smear, transvaginal sonography and endometrial biopsy. Endometrial carcinoma and cervical carcinoma were excluded. LNG-IUS was inserted in the postmenstrual phase. Blood loss was assessed by pictorial blood loss assessment chart (PBAC). They were followed up after 3 months, 6 months, and after 1 year.Results:Majority of the women had menstrual spotting for 3–4 months followed by infrequent menstruation, scanty menstruation or amenorrhoea. LNG-IUS was removed because of continued bleeding in two cases and was removed because of displacement in one case. It was expelled spontaneously in four cases. Thirty-three women continued to use LNG-IUS.Conclusion:LNG-IUS is a safe and effective option for women with menorrhagia due to benign lesions of the uterus in perimenopausal women.